Factors Associated With Persistence of Plasma HIV-1 RNA During Long-term Continuously Suppressive Firstline Antiretroviral Therapy

Abstract Background Persistence of plasma HIV-1 RNA during seemingly effective antiretroviral thereapy (ART) is incompletely understood. Using an ultrasensitive assay, this cross-sectional study investigated residual plasma HIV-1 RNA in subjects maintained on firstline ART with continuous viral load suppression <50 copies/mL for ≤15 years without recognized viral load blips or treatment interruptions and explored its relationship with the duration of suppressive ART, efavirenz concentrations in plasma, 2-LTR circular HIV-1 DNA (2-LTRc DNA) in peripheral blood mononuclear cells, and cellular (CD4 plus CD26/CD38/CD69; CD8 plus CD38/HLA-DR/DP/DQ) and soluble (sCD14, sCD27, sCD30, IL-6) markers of immune activation in peripheral blood. Methods Residual plasma HIV-1 RNA, total HIV-1 DNA and 2-LTRc DNA were quantified by real-time and digital droplet PCR. Cellular (CD4 plus CD26/CD38/CD69; CD8 plus CD38/HLA-DR/DP/DQ) and soluble (sCD14, sCD27, sCD30, IL-6) markers of immune activation were measured by flow cytometry and ELISA. Results Residual plasma HIV-1 RNA and 2-LTRc DNA were detected in 52/104 (50%) and 24/104 (23%) subjects, respectively. Among subjects with detectable HIV-1 RNA, 50/52 showed levels ≤11 copies/mL. In adjusted analyses, HIV-1 RNA levels were 0.37 log10 copies/mL higher with each log10 U/mL increase in sCD27 (95% confidence interval, 0.01–0.73; P = .02). No significant association was found between residual plasma HIV-1 RNA and other explored parameters. Conclusions These findings point to an ongoing relationship between plasma HIV-1 RNA and selected markers of immune activation during continuously suppressive ART. The novel direct association with levels of sCD27 warrants further investigation.

[1]  J. Mellors,et al.  Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation , 2017, PLoS pathogens.

[2]  J. Mullins,et al.  Clonal Expansion of Human Immunodeficiency Virus-Infected Cells and Human Immunodeficiency Virus Persistence During Antiretroviral Therapy. , 2017, The Journal of infectious diseases.

[3]  S. Lewin,et al.  Human Immunodeficiency Virus Persistence and T-Cell Activation in Blood, Rectal, and Lymph Node Tissue in Human Immunodeficiency Virus–Infected Individuals Receiving Suppressive Antiretroviral Therapy , 2017, The Journal of infectious diseases.

[4]  R. Hintzen,et al.  Soluble CD27 Levels in Cerebrospinal Fluid as a Prognostic Biomarker in Clinically Isolated Syndrome , 2017, JAMA neurology.

[5]  J. Lambert,et al.  Clinical Significance of Serum Soluble CD Molecules to Assess Disease Activity in Vitiligo. , 2016, JAMA dermatology.

[6]  F. Guilford,et al.  Data on pro-inflammatory cytokines IL-1β, IL-17, and IL-6 in the peripheral blood of HIV-infected individuals , 2016, Data in brief.

[7]  C. Leen,et al.  Discordant CSF/plasma HIV-1 RNA in patients with unexplained low-level viraemia , 2016, Journal of NeuroVirology.

[8]  Steven G. Deeks,et al.  Persistent HIV-1 replication during antiretroviral therapy , 2016, Current opinion in HIV and AIDS.

[9]  O. Uysal,et al.  Neopterin and Soluble CD14 Levels as Indicators of Immune Activation in Cases with Indeterminate Pattern and True Positive HIV-1 Infection , 2016, PloS one.

[10]  M. Altfeld,et al.  Immune activation and HIV: an enduring relationship. , 2016, Current opinion in HIV and AIDS.

[11]  K. Duedu,et al.  Decay of Soluble CD30 and HIV-1 Plasma Viral Load during Early Highly Active Antiretroviral Therapy: A Short-Term Longitudinal Study , 2016 .

[12]  F. Vaida,et al.  Continued Slow Decay of the Residual Plasma Viremia Level in HIV-1-Infected Adults Receiving Long-term Antiretroviral Therapy. , 2016, The Journal of infectious diseases.

[13]  Trevor Bedford,et al.  Persistent HIV-1 replication maintains the tissue reservoir during therapy , 2015, Nature.

[14]  A. Phillips,et al.  Factors Associated With Plasma IL-6 Levels During HIV Infection. , 2015, The Journal of infectious diseases.

[15]  Wei Sun,et al.  Elevated Serum Levels of Soluble CD30 in Ankylosing Spondylitis Patients and Its Association with Disease Severity-Related Parameters , 2015, BioMed research international.

[16]  D. Richman,et al.  During Stably Suppressive Antiretroviral Therapy Integrated HIV-1 DNA Load in Peripheral Blood is Associated with the Frequency of CD8 Cells Expressing HLA-DR/DP/DQ , 2015, EBioMedicine.

[17]  J. Margolick,et al.  Kidney Dysfunction and Markers of Inflammation in the Multicenter AIDS Cohort Study. , 2015, The Journal of infectious diseases.

[18]  J. Mellors,et al.  Changes in HIV reservoirs during long-term antiretroviral therapy , 2015, Current opinion in HIV and AIDS.

[19]  J. Mellors,et al.  HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  R. Siliciano,et al.  CD4+ and CD8+ T Cell Activation Are Associated with HIV DNA in Resting CD4+ T Cells , 2014, PloS one.

[21]  Alan S Perelson,et al.  Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues , 2014, Proceedings of the National Academy of Sciences.

[22]  P. Lemey,et al.  The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time , 2013, Proceedings of the National Academy of Sciences.

[23]  Jeffrey N. Martin,et al.  Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)-expressing CD4+ T cells. , 2013, The Journal of infectious diseases.

[24]  D. Douek,et al.  Immune activation and HIV persistence: implications for curative approaches to HIV infection , 2013, Immunological reviews.

[25]  S. Steinberg,et al.  Soluble CD27-Pool in Humans May Contribute to T Cell Activation and Tumor Immunity , 2013, The Journal of Immunology.

[26]  H. Hatano.  Immune activation and HIV persistence: considerations for novel therapeutic interventions , 2013, Current opinion in HIV and AIDS.

[27]  Douglas D. Richman,et al.  Highly Precise Measurement of HIV DNA by Droplet Digital PCR , 2013, PloS one.

[28]  R. Siliciano,et al.  Comparative Analysis of Measures of Viral Reservoirs in HIV-1 Eradication Studies , 2013, PLoS pathogens.

[29]  A. Phillips,et al.  Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  A. Geretti,et al.  Low-level viraemia on HAART: significance and management , 2012, Current opinion in infectious diseases.

[31]  J. Ribeiro,et al.  Plasma concentrations of efavirenz are associated with body weight in HIV-positive individuals. , 2011, The Journal of antimicrobial chemotherapy.

[32]  Handan Wand,et al.  Plasma levels of soluble CD14 independently predict mortality in HIV infection. , 2011, The Journal of infectious diseases.

[33]  M. Wallet,et al.  Microbial translocation induces persistent macrophage activation unrelated to HIV-1 levels or T-cell activation following therapy , 2010, AIDS.

[34]  R. Weber,et al.  Prevalence of comedications and effect of potential drug–drug interactions in the Swiss HIV Cohort Study , 2010, Antiviral therapy.

[35]  R. V. van Lier,et al.  Timing and tuning of CD27–CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology , 2009, Immunological reviews.

[36]  J. Mellors,et al.  Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy , 2008, Proceedings of the National Academy of Sciences.

[37]  R. V. van Lier,et al.  CD27-CD70 interactions sensitise naive CD4+ T cells for IL-12-induced Th1 cell development. , 2007, International immunology.

[38]  Joseph A Kovacs,et al.  ART Suppresses Plasma HIV-1 RNA to a Stable Set Point Predicted by Pretherapy Viremia , 2007, PLoS pathogens.

[39]  F. Chiodi,et al.  Effects of potent antiretroviral therapy on the immune activation marker soluble CD27 in patients infected with HIV‐1 subtypes A–D , 2004, Journal of medical virology.

[40]  F. Bushman,et al.  Human Immunodeficiency Virus cDNA Metabolism: Notable Stability of Two-Long Terminal Repeat Circles , 2002, Journal of Virology.

[41]  Tara L. Kieffer,et al.  Intrinsic Stability of Episomal Circles Formed during Human Immunodeficiency Virus Type 1 Replication , 2002, Journal of Virology.

[42]  F. Chiodi,et al.  Plasma levels of soluble CD27: a simple marker to monitor immune activation during potent antiretroviral therapy in HIV‐1‐infected subjects , 2002, Clinical and experimental immunology.

[43]  R. Detels,et al.  Aberrant expression of CD27 and soluble CD27 (sCD27) in HIV infection and in AIDS-associated lymphoma. , 1999, Clinical immunology.

[44]  T. Greenough,et al.  High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. , 1995, The Journal of infectious diseases.

[45]  I. T. Ten Berge,et al.  A soluble form of the human T cell differentiation antigen CD27 is released after triggering of the TCR/CD3 complex. , 1991, Journal of immunology.

[46]  J. Arribas,et al.  Dynamics of cellular HIV-1 DNA levels over 144 weeks of darunavir/ritonavir monotherapy versus triple therapy in the MONET trial. , 2012, HIV clinical trials.

[47]  John L. Sullivan,et al.  Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy , 2000, Nature Medicine.